NCT01910649
A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2008
Completion: Sep 30, 2016